Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Revance Therapeutics (RVNC) to Release Q4 and Full Year 2023 Financial Results on February 28, 2024, with a Conference Call and Webcast to Discuss Results and Corporate Update.
02/21/2024 - 08:01 AM
Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET.
NASHVILLE, Tenn. --(BUSINESS WIRE)--
Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 643827, or from the webcast link in the investor relations section of the company's website at: www.revance.com .
A webcast replay will be available beginning February 28, 2024, at 4.30 p.m. PT / 7.30 p.m. ET to May 28, 2024, at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China .
Revance is headquartered in Nashville, Tenn. , with additional office locations in Newark and Irvine, Calif. Learn more at Revance.com , RevanceAesthetics.com , DAXXIFY.com , HCP.DaxxifyTherapy.com , or connect with us on LinkedIn .
“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221311035/en/
Investors
Revance Therapeutics, Inc.:
Jessica Serra, 510-279-6886
jessica.serra@revance.com
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com
Media
Revance Therapeutics, Inc.:
Cathryn Castaldo, 615-245-7567
cathryn.castaldo@revance.com
Source: Revance Therapeutics, Inc.
Revance Therapeutics will release its Q4 and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market.
The conference call and live webcast to discuss the results and provide a corporate update will be held at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Interested individuals can listen to the conference call by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations, or through the webcast link on the company's website.
The webcast replay will be available starting February 28, 2024, at 4:30 p.m. PT / 7:30 p.m. ET until May 28, 2024, at 4:30 p.m. PT / 7:30 p.m. ET.
The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
RVNC Rankings
#5006 Ranked by Stock Gains
RVNC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Newark
About RVNC
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form